A phase 2, open-label study of S-646240 in patients with age-related macular degeneration accompanied by choroidal neovascularizatio
Phase 2
- Conditions
- Age-related macular degeneration
- Registration Number
- JPRN-UMIN000008040
- Lead Sponsor
- Shionogi & Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who have CNV due to other causes than age. (2) Patients who have previous or present retinal vessel disease other than AMD.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
S-646240 Shionogi mechanism action targeting pathways choroidal neovascularization wet AMD
Comparative efficacy S-646240 versus anti-VEGF therapy wet AMD phase 2 outcomes
Predictive biomarkers OCT genetics treatment response choroidal neovascularization novel agents AMD
Safety profile management adverse events novel therapies wet AMD CNV Shionogi
Emerging therapeutic targets beyond VEGF wet AMD angiogenesis fibrosis inflammation pipeline